November 2021
AAM Magazine
November 2021
Back to news

Hong Kong’s Raffles Family Office leads fundraising round for biotech firm Cellomics

Hong Kong
Other investors in this fundraising round include Hong Kong-listed Jacobson Pharma and Shenzhen-listed Sinocare
By Goh Thean Eu   
September 27, 2021

Hong Kong-based Raffles Family Office (RFO) led a fundraising round for local biotechnology company Cellomics, which drew investors including locally-listed Hong Kong-listed Jacobson Pharma and Shenzhen-listed Sinocare.

The multi-family office did not disclose how much money was raised or provide more details.

"Our Cellomics stake further addresses rising interest among our clients in direct investment opportunities, but more importantly lets us showcase the strength of Hong Kong as a hub for new ideas," Kwan Chi Man, co-founder and group chief executive officer of Raffles Family Office, says in a statement on September 24.

Michael Yang, chairman and co-founder of Cellomics, says the investment will accelerate the firm’s growth and take it a step closer to its goal of offering “unique and potentially life-saving solutions to radically improve cancer screening, monitoring and treatment".